Selecting COVID‐19 convalescent plasma for neutralizing antibody potency using a high‐capacity SARS‐CoV‐2 antibody assay
…, M Stone, P Contestable, A Prichard… - …, 2021 - Wiley Online Library
Background Efficacy of COVID‐19 convalescent plasma (CCP) is hypothesized to be associated
with the concentration of neutralizing antibodies (nAb) to SARS‐CoV‐2. High capacity …
with the concentration of neutralizing antibodies (nAb) to SARS‐CoV‐2. High capacity …
The effect of COVID‐19 on blood donation habits
RR Gammon, AB Prichard, MS Gannett… - Transfusion, 2021 - Wiley Online Library
Background Blood centers (BCs) rely on schools and businesses. Shelter‐in‐place orders
closed them. This study determined how COVID‐19 affected donation habits. Study Design …
closed them. This study determined how COVID‐19 affected donation habits. Study Design …
Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern US blood center's experience
…, Y Wu, L Reed, M Rogers, A Prichard… - Journal of clinical …, 2021 - Wiley Online Library
Background During the pandemic in the spring of 2020 with no vaccine or treatment for
SARS‐CoV‐2 and its associated disease, COVID‐19, convalescent plasma from recovered …
SARS‐CoV‐2 and its associated disease, COVID‐19, convalescent plasma from recovered …
Patient blood management during a pandemic-the patient wins
…, K Counts, B Yordanov, AB Prichard - Anesthesia and …, 2020 - journals.lww.com
Background: When COIVD-19 became a pandemic, blood center (BC) and hospitals implemented
business continuity plans (BCP). The pandemic resulted in decreased blood demand. …
business continuity plans (BCP). The pandemic resulted in decreased blood demand. …
Manufacturing Turnaround Time
J McCoun, W Lindblom, K McIntosh, AB Prichard… - …, 2022 - pesquisa.bvsalud.org
Background/Case Studies The need for group O blood has increased by 20% over the last
few years and the demand for O blood was felt the most during the early stages of the COVID-…
few years and the demand for O blood was felt the most during the early stages of the COVID-…
Characterization of SARS-CoV-2 antibody titers in over 6,000 blood and plasma donations
M Gannett, S Viana, N Benitez, AB Prichard… - …, 2020 - pesquisa.bvsalud.org
Background/Case Studies Neutralizing antibodies to SARS-CoV-2 are believed to have a
Spike protein specificity, specifically to the Receptor Binding Domain of Subunit 1 (S1-RBD). …
Spike protein specificity, specifically to the Receptor Binding Domain of Subunit 1 (S1-RBD). …
Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs LVDS Screened Platelets
AB Prichard, H Requena, K Medina, C Pollei… - 2022 Annual …, 2022 - intercept-usa.com
Aims We demonstrated that earlier release of PR PC translates to sooner availability,
equivalent or better shelf-life, and transfusion of fresher PC for patients vs LVDS. Inventory …
equivalent or better shelf-life, and transfusion of fresher PC for patients vs LVDS. Inventory …
The effect of COVID-19 on donation habits of donors
R Gammon, AB Prichard, M Gannett… - Transfusion, 2020 - pesquisa.bvsalud.org
Background/Case Studies Blood centers (BC) rely on collections at schools and businesses.
Shelter-in-place orders issued in 2020 due to COVID-19 closed these facilities. Additional …
Shelter-in-place orders issued in 2020 due to COVID-19 closed these facilities. Additional …
[CITATION][C] Qualification of Amustaline-Gsh Red Blood Cell Pathogen Reduction System for a Phase 3 Clinical Trial
AB Prichard, M Kuhn, P Linares, J McCoun… - 2018 Annual …, 2018 - aabb.confex.com
[CITATION][C] The Influence of COVID-19 Vaccinations and Previous Infection on Donor anti-Sars-Cov-2 Titers
R Gammon, M Gannett, AB Prichard, RA Reik - Transfusion, 2021 - pesquisa.bvsalud.org
The Influence of COVID-19 Vaccinations and Previous Infection on Donor anti-Sars-Cov-2
Titers | Transfusion; 61:76A-77A, 2021. | Web of Science Conteúdo principal 1 Busca 2 Rodapé …
Titers | Transfusion; 61:76A-77A, 2021. | Web of Science Conteúdo principal 1 Busca 2 Rodapé …